HK inno.N Corporation

A195940

KR7195940002

Pharmaceuticals

End-of-day quote Korea S.E. Other stock markets 06:00:00 2024-04-29 pm EDT			5-day change	1st Jan Change
38,750 ^KRW	-1.27%		+2.51%	-12.82%

2022	Sebela Pharmaceuticals® Acquires Exclusive Licensing Rights from HK inno.N Corporation to Develop and Commercialize Tegoprazan in the U.S. and Canada	CI
2022	Sebela Pharmaceuticals Enters an Exclusive Partnership with HK inno.N Corporation	CI

HK inno.N Corporation(KOSDAQ:A195940) added to S&P Global BMI Index

December 20, 2021 at 12:00 am EST

Latest news about HK inno.N Corporation

Sebela Pharmaceuticals® Acquires Exclusive Licensing Rights from HK inno.N Corporation to Develop and Commercialize Tegoprazan in the U.S. and Canada	22-10-27	CI
Sebela Pharmaceuticals Enters an Exclusive Partnership with HK inno.N Corporation	22-10-19	CI
Tranche Update on HK inno.N Corporation's Equity Buyback Plan announced on February 9, 2022.	22-08-09	CI
Tranche Update on HK inno.N Corporation's Equity Buyback Plan announced on February 9, 2022.	22-08-09	CI
HK inno.N Corporation's Equity Buyback announced on February 9, 2022, has expired with 574,608 shares, representing 1.99% for KRW 24,180.98 million.	22-08-08	CI
Indian Indices Close in the Red Midweek; Shree Cement Slides 4%	22-05-11	MT
Tranche Update on HK inno.N Corporation's Equity Buyback Plan announced on February 9, 2022.	22-05-11	CI
Dr. Reddy's to Market HK inno.N's Gastrointestinal Diseases Drug in India, Emerging Markets	22-05-11	MT
Dr. Reddy's Laboratories Ltd. Enters into an Exclusive Partnership with South Korea-Based HK Inno.N Corporation	22-05-10	CI
HK inno.N's Gastroesophageal Reflux Disease Drug Gets Marketing Approval in China	22-04-17	MT
Y-Biologics Inc. announced that it expects to receive KRW 30 billion in funding from a group of investors	22-02-23	CI
HK inno.N Corporation announces an Equity Buyback for KRW 24,200 million worth of its shares.	22-02-09	CI
HK inno.N Corporation authorizes a Buyback Plan.	22-02-08	CI
Kolmar Korea to Acquire 40% Stake in Biotech Firm Next & Bio	21-12-30	MT
South Korea's Secondary Stock Market Adds Largest Number of New Tech IPOs in 2021	21-12-28	MT
HK inno.N Enters License Agreement for Gastroesophageal Reflux Drug in the US	21-12-26	MT
HK inno.N Corporation(KOSDAQ:A195940) added to S&P Global BMI Index	21-12-20	CI
HK inno.N Corporation has completed an IPO in the amount of KRW 596.903 billion.	21-08-03	CI
HK inno.N Corporation has filed an IPO.	21-05-04	CI
HK inno.N Corporation announced that it has received KRW 49.9999765 billion in funding from Kolmar Korea Co., Ltd.	21-04-21	CI
HK inno.N Corporation announced that it expects to receive KRW 49.9999765 billion in funding from Kolmar Korea Co., Ltd.	21-04-20	CI
Raqualia Pharma Inc. Announces an Expansion of the Strategic Alliance with CJ Healthcare Corp	19-11-28	CI
CKM Co., Ltd. completed the acquisition of CJ HealthCare Corp from CJ Cheiljedang Corporation.	18-04-17	CI
CKM Co., Ltd. signed an agreement to acquire CJ HealthCare Corp from CJ Cheiljedang Corporation for KRW 1.3 trillion.	18-02-19	CI
CJ Cheiljedang Seeks To Sell CJ Healthcare	17-11-05	CI

HK Inno.N Corp is a Korea-based company mainly engaged in the manufacture and sale of prescription drugs. The Company operates its business through three segments. The Prescription Drug segment is engaged in the manufacture and sale of hormone drugs, anticancer drugs, high blood pressure drugs, gastroesophageal reflux disease drugs, blood nutrient supplies, the circulatory system and others. The Health Beauty and Beverage (HB&B) segment is engaged in the manufacture and sale of products such as hangover relieving products, as well as health drinks and food products. The Other segment is engaged in the trademark royalties business and other services. The Company sells its products within domestic market and to overseas markets.

Sector

Pharmaceuticals

Calendar

2024-05-05 - Q1 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for HK inno.N Corporation

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

38,750 KRW

Average target price

53,750 KRW

Spread / Average Target

+38.71%

Consensus

EPS Revisions

Estimates Revisions

Quarterly revenue - Rate of surprise

Company calendar

Sector Specialty & Advanced Pharmaceuticals

	1st Jan change	Capi.
HK INNO.N CORPORATION	-12.82%	793M
MERCK KGAA	+3.37%	69.25B
KYOWA KIRIN CO. LTD.	+12.55%	9B
SK BIOPHARMACEUTICALS CO., LTD.	-12.75%	4.96B
SHENYANG XINGQI PHARMACEUTICAL CO.,LTD.	+42.38%	4.47B
YUHAN CORPORATION	+5.23%	3.9B
INDIVIOR PLC	+19.75%	2.45B
BETTA PHARMACEUTICALS CO., LTD.	-19.05%	2.41B
CHANGCHUN BCHT BIOTECHNOLOGY CO.	-28.72%	2.23B
SHANGHAI SHYNDEC PHARMACEUTICAL CO., LTD.	+11.13%	2.02B

Specialty & Advanced Pharmaceuticals